Kava as a Clinical Nutrient: Promises and Challenges
Open Access
- 5 October 2020
- Vol. 12 (10), 3044
- https://doi.org/10.3390/nu12103044
Abstract
Kava beverages are typically prepared from the root of Piper methysticum. They have been consumed among Pacific Islanders for centuries. Kava extract preparations were once used as herbal drugs to treat anxiety in Europe. Kava is also marketed as a dietary supplement in the U.S. and is gaining popularity as a recreational drink in Western countries. Recent studies suggest that kava and its key phytochemicals have anti-inflammatory and anticancer effects, in addition to the well-documented neurological benefits. While its beneficial effects are widely recognized, rare hepatotoxicity had been associated with use of certain kava preparations, but there are no validations nor consistent mechanisms. Major challenges lie in the diversity of kava products and the lack of standardization, which has produced an unmet need for quality initiatives. This review aims to provide the scientific community and consumers, as well as regulatory agencies, with a broad overview on kava use and its related research. We first provide a historical background for its different uses and then discuss the current state of the research, including its chemical composition, possible mechanisms of action, and its therapeutic potential in treating inflammatory and neurological conditions, as well as cancer. We then discuss the challenges associated with kava use and research, focusing on the need for the detailed characterization of kava components and associated risks such as its reported hepatotoxicity. Lastly, given its growing popularity in clinical and recreational use, we emphasize the urgent need for quality control and quality assurance of kava products, pharmacokinetics, absorption, distribution, metabolism, excretion, and foundational pharmacology. These are essential in order to inform research into the molecular targets, cellular mechanisms, and creative use of early stage human clinical trials for designer kava modalities to inform and guide the design and execution of future randomized placebo controlled trials to maximize kava’s clinical efficacy and to minimize its risks.Keywords
This publication has 175 references indexed in Scilit:
- Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosisMolecular Cancer, 2013
- Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell linesJournal of Orthopaedic Research, 2011
- Kava, the anxiolytic herb: back to basics to prevent liver injury?British Journal of Clinical Pharmacology, 2011
- Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signaling pathwaysThe FASEB Journal, 2010
- Flavokawain B, a novel chalcone from Alpinia pricei Hayata with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116 cellsFree Radical Biology & Medicine, 2010
- Identification of methysticin as a potent and non-toxic NF-κB inhibitor from kava, potentially responsible for kava’s chemopreventive activityBioorganic & Medicinal Chemistry Letters, 2009
- Identification and Characterization of Kava‐derived Compounds Mediating TNF‐α SuppressionChemical Biology & Drug Design, 2009
- Effects of the Kava Chalcone Flavokawain A Differ in Bladder Cancer Cells with Wild-type versus Mutant p53Cancer Prevention Research, 2008
- Confirmatory factor analysis of the Minnesota Nicotine Withdrawal Scale.Psychology of Addictive Behaviors, 2007
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005